Kuehn Law is investigating whether certain officers and directors of Corcept Therapeutics Incorporated breached their fiduciary duties to shareholders. The investigation follows a federal securities lawsuit alleging the company failed to disclose that the FDA had expressed concerns about the adequacy of its clinical development program for relacorilant, a lead product candidate for hypercortisolism, and that its New Drug Application faced a material risk of rejection. Shareholders who purchased Corcept Therapeutics stock prior to October 31, 2024 are encouraged to contact the law firm.
Corcept Therapeutics IncorporatedInvestigation and lawsuit allege FDA concerns about relacorilant's clinical program and NDA rejection risk.